These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24704469)

  • 1. Impact of myocardial bridging on the long-term clinical outcomes of patients with left anterior descending coronary artery disease treated with a drug-eluting stent.
    Lee CH; Kim U; Park JS; Kim YJ
    Heart Lung Circ; 2014 Aug; 23(8):758-63. PubMed ID: 24704469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1242-9. PubMed ID: 24355114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up.
    Wang CH; Fang Q; Zhang SY; Shen ZJ; Fan ZJ; Jin XF; Zeng Y; Liu ZY; Xie HZ; Yang M
    Chin Med J (Engl); 2012 Aug; 125(16):2803-6. PubMed ID: 22932070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
    Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
    Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year angiographic and clinical follow-up of patients with drug-eluting stent implantation for symptomatic myocardial bridging in absence of coronary atherosclerotic disease.
    Ernst A; Bulum J; Šeparović Hanževački J; Lovrić Benčić M; Strozzi M
    J Invasive Cardiol; 2013 Nov; 25(11):586-92. PubMed ID: 24184893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of gender on clinical outcomes after mTOR-inhibitor drug-eluting stent implantation in patients with first manifestation of ischaemic heart disease.
    Niccoli G; Sgueglia GA; Cosentino N; Piro M; Toma A; Cataneo L; Fracassi F; Porto I; Leone AM; Burzotta F; Trani C; Crea F
    Eur J Prev Cardiol; 2012 Oct; 19(5):914-26. PubMed ID: 21840968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes after stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 10-year results of bare-metal stents and 5-year results of drug-eluting stents from the ASAN-MAIN (ASAN Medical Center-Left MAIN Revascularization) Registry.
    Park DW; Kim YH; Yun SC; Lee JY; Kim WJ; Kang SJ; Lee SW; Lee CW; Kim JJ; Choo SJ; Chung CH; Lee JW; Park SW; Park SJ
    J Am Coll Cardiol; 2010 Oct; 56(17):1366-75. PubMed ID: 20946993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of metabolic syndrome on clinical outcomes after new generation drug-eluting stent implantation: the 'obesity paradox' phenomenon is still apparent.
    Patsa C; Toutouzas K; Tsiamis E; Tsioufis C; Spanos A; Karanasos A; Michelongona A; Tousoulis D; Stefanadis C
    Nutr Metab Cardiovasc Dis; 2013 Apr; 23(4):307-13. PubMed ID: 21917434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term results of unprotected left main percutaneous coronary intervention with DES versus BMS.
    Capodanno D; Di Salvo ME; Capranzano P; Seminara D; Caggegi A; Barrano G; Tamburino C
    Minerva Cardioangiol; 2009 Feb; 57(1):1-6. PubMed ID: 19202514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical outcomes between octogenarians and non-octogenarians with acute myocardial infarction in the drug-eluting stent era: analysis of the Korean Acute Myocardial Infarction Registry.
    Yamanaka F; Jeong MH; Saito S; Ahn Y; Chae SC; Hur SH; Hong TJ; Kim YJ; Seong IW; Chae JK; Rhew JY; Chae IH; Cho MC; Bae JH; Rha SW; Kim CJ; Choi D; Jang YS; Yoon J; Chung WS; Cho JG; Seung KB; Park SJ;
    J Cardiol; 2013 Oct; 62(4):210-6. PubMed ID: 23731919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of drug-eluting versus bare-metal stent implantation in patients with chronic total coronary artery occlusions.
    Han YL; Zhang J; Li Y; Wang SL; Jing QM; Yi XH; Ma YY; Luan B; Wang G; Wang B
    Chin Med J (Engl); 2009 Mar; 122(6):643-7. PubMed ID: 19323927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy comparison between drug-eluting stents versus cutting balloon angioplasty followed by bare metal stents for the treatment of ostial lesions of the left anterior descending coronary artery].
    Chen JL; Gao LJ; Gao RL; Yang YJ; Qin XW; Qiao SB; Xu B; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Aug; 36(8):702-5. PubMed ID: 19100110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes after treating acute coronary syndrome patients with a drug-eluting stent: results from REWARDS-EMI (Endeavor for Myocardial Infarction Registry).
    Dvir D; Barbash IM; Torguson R; Badr S; Sardi GL; Laynez-Carnicero A; Ben-Dor I; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2013; 14(3):128-33. PubMed ID: 23642502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents following successful PCI in non-ST-elevation myocardial infarction: findings from the Guthrie Health Off-Label StenT (GHOST) Registry.
    Harjai KJ; Sattur S; Orshaw P; Boura J
    J Interv Cardiol; 2012 Feb; 25(1):28-36. PubMed ID: 21981467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease.
    Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Naim C; Kawaguchi M; Giannini F; Colombo A
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1153-9. PubMed ID: 24262615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of admission creatinine level on clinical outcomes of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stent implantation.
    Zhang Q; Zhang RY; Shen J; Zhang JS; Hu J; Yang ZK; Zhang X; Zheng AF; Shen WF
    Chin Med J (Engl); 2008 Dec; 121(23):2379-83. PubMed ID: 19102952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.